ArticleDiscover oncology2026
Biological fact versus technical artifact in ER negative PR positive breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEstrogen receptor (ER) negative/progesterone receptor (PR) positive is an infrequently reported biological subtype of breast cancer (BC). Various authors have treated its existence doubtfully. To our knowledge, this study is the first within Egypt and the Middle East to investigate this rare subgroup of BC.
methodsThis retrospective study included all ER-/PR + BC patients treated in our center from 2016 to 2022. The collected data were coded, processed, and analyzed using IBM SPSS.
resultsThe study included 149 patients with ER-/PR + breast cancer. The mean age was 50.3 years (21-83). The mean follow-up interval was 68 months. pT1 represented 20.8% of the cases, pT2 tumors were 50%, pT3 tumors were 16.7%, while pT4 tumors were 5.6%. As regards nodal staging, pN0 were 36.3%, pN1 24.7%, pN2 19.2%, and pN3 19.8%. The main histology of the tumors was infiltrating duct carcinoma (81.2%), followed by lobular carcinoma (8.7%). Weak PR positivity (Allred score < 6) was documented in 92 patients (61.7%). While the remaining patients showed strong PR positivity (scores of 6 or higher), 68% were HER2 receptor-negative. In the follow-up period, 39% of the patients suffered from disease relapse. The mean disease-free survival was 60.8 months, and the mean overall survival was 69.8 months. The nodal status was the only variable that significantly affected disease-free and overall survival in the univariate analysis, while no factor affected survival in the multivariate analysis.
conclusionER-/PR + breast cancer seems to be an underestimated subtype, which is more aggressive than double-positive hormonal receptor breast cancer but less aggressive than double-negative hormonal receptor breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.